BETA

ARCA biopharma

ABIO58

Penny Stock

$3.14arrow_drop_up2.28%$0.07

Penny Stock

ABIO58

$3.14

arrow_drop_up2.28%$0.07

Penny Stock

Performance History

Key Stats
Open	$3.13
Prev. Close	$3.12
EPS	-0.42
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$47.29M
PE Ratio	-

	LOW	HIGH
Day Range	3.01	3.20
52 Week Range	1.56	4.49

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.42

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

Correlated Companies

Eli Lilly & Co

LLY74

Price$804.62

Perf. (24h)

arrow_drop_down2.01%-$16.57

Market Cap$724.48B

UnitedHealth Group

UNH71

Price$569.71

Perf. (24h)

arrow_drop_up1.79%$10.03

Market Cap$527.83B

Johnson & Johnson

JNJ62

Price$160.64

Perf. (24h)

arrow_drop_up0.62%$1.00

Market Cap$386.60B

AbbVie

ABBV62

Price$185.16

Perf. (24h)

arrow_drop_up1.64%$2.99

Market Cap$326.96B

About ARCA biopharma (ABIO)

ARCA biopharma Inc (ABIO) is a biopharmaceutical company that focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's primary focus is on developing therapies for atrial fibrillation (AFib), which is a common type of arrhythmia that affects millions of people worldwide. ARCA's lead product candidate, AB201, is designed to treat AFib by targeting a specific genetic mutation known as G protein beta-3 (GNB3). This mutation is believed to be a key driver of AFib and is present in a significant percentage of patients with the condition.

In recent years, ARCA has made significant progress in the development of AB201. The company has successfully completed several clinical trials, demonstrating the safety and efficacy of the drug in patients with AFib. These trials have shown that AB201 can effectively restore normal heart rhythm and reduce the risk of AFib-related complications. In addition to AFib, ARCA is also exploring the potential of AB201 in other cardiovascular diseases, such as heart failure.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Michael R. Bristow M.D., Ph.D.
Headquarters: Westminster
Employees: 5
Exchange: NASDAQ

Keep an eye on ARCA biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the 52-week high and low for ARCA biopharma (ABIO)?

For ARCA biopharma (ABIO), the 52-week high is $4.49, which is 42.99% from the current price. The 52-week low is $1.56, the current price is 101.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is ARCA biopharma 's (ABIO) price per share?

The current price per share for ARCA biopharma (ABIO) is $3.14. The stock has seen a price change of $0.07 recently, indicating a 2.28% change. This reflects the stock's recent market performance and investor sentiment.

help

Is ARCA biopharma (ABIO) a growth stock?

ARCA biopharma (ABIO) has shown an average price growth of 0.41% over the past three years. It has received a score of 74 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ARCA biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ARCA biopharma (ABIO) stock price performance year to date (YTD)?

As of the latest data, ARCA biopharma (ABIO) has a year-to-date price change of 87.13%. Over the past month, the stock has experienced a price change of -9.54%. Over the last three months, the change has been -12.29%. Over the past six months, the figure is 86.35%. Looking at a longer horizon, the five-year price change stands at -53.82%.

help

Is ARCA biopharma (ABIO) a profitable company?

ARCA biopharma (ABIO) has a net income of -$5.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$7.3M. Furthermore, the EBITDA is -$7.97M.

help

What is the market capitalization of ARCA biopharma (ABIO)?

ARCA biopharma (ABIO) has a market capitalization of $45.55M. The average daily trading volume is 129.46K, indicating the stock's liquidity and investor engagement.

News

Citizens And 4 Other Stocks Under $5 Insiders Are Buying - Benzinga

WILLAMETTE VALLEY VINEYARDS

CYANOTECH

DOUGLAS ELLIMAN

7/15/2024

Citizens And 4 Other Stocks Under $5 Insiders Are Buying - Benzinga

Kintara Therapeutics restructures share designations By Investing.com - Investing.com Australia

Kintara Therapeutics restructures share designations By Investing.com - Investing.com Australia

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

EARNINGS RELEASES AND OPERATING RESULTS

MERGERS AND ACQUISITIONS

RESTRUCTURING / RECAPITALIZATION

4/25/2024

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket

Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket

Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat Earnings

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

Correlated Companies

About ARCA biopharma (ABIO)

Keep an eye on ARCA biopharma

Frequently Asked Questions

What is the 52-week high and low for ARCA biopharma (ABIO)?

What is ARCA biopharma 's (ABIO) price per share?

Is ARCA biopharma (ABIO) a growth stock?

What is ARCA biopharma (ABIO) stock price performance year to date (YTD)?

Is ARCA biopharma (ABIO) a profitable company?

What is the market capitalization of ARCA biopharma (ABIO)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level